BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 21715317)

  • 1. Differential and tumor-specific expression of CD160 in B-cell malignancies.
    Farren TW; Giustiniani J; Liu FT; Tsitsikas DA; Macey MG; Cavenagh JD; Oakervee HE; Taussig D; Newland AC; Calaminici M; Bensussan A; Jenner M; Gribben JG; Agrawal SG
    Blood; 2011 Aug; 118(8):2174-83. PubMed ID: 21715317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of CD160 and CD200 as a useful tool for differential diagnosis between chronic lymphocytic leukemia and other mature B-cell neoplasms.
    Lesesve JF; Tardy S; Frotscher B; Latger-Cannard V; Feugier P; De Carvalho Bittencourt M
    Int J Lab Hematol; 2015 Aug; 37(4):486-94. PubMed ID: 25470765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The immunophenotypic characteristics of 260 patients with CD5 + B cell lymphoproliferative disorders].
    Yi S; Li Z; Wang H; Liu W; Lyu R; Yu Z; Qi J; Qiu L
    Zhonghua Xue Ye Xue Za Zhi; 2014 Apr; 35(4):337-41. PubMed ID: 24759024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation.
    Sánchez ML; Almeida J; Vidriales B; López-Berges MC; García-Marcos MA; Moro MJ; Corrales A; Calmuntia MJ; San Miguel JF; Orfao A
    Leukemia; 2002 Aug; 16(8):1460-9. PubMed ID: 12145686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD160 receptor in CLL: Current state and future avenues.
    Oumeslakht L; Aziz AI; Bensussan A; Ben Mkaddem S
    Front Immunol; 2022; 13():1028013. PubMed ID: 36420268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD5+ B-cell lymphoproliferative disorders: Beyond chronic lymphocytic leukemia and mantle cell lymphoma.
    Jevremovic D; Dronca RS; Morice WG; McPhail ED; Kurtin PJ; Zent CS; Hanson CA
    Leuk Res; 2010 Sep; 34(9):1235-8. PubMed ID: 20362334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL.
    Matutes E; Owusu-Ankomah K; Morilla R; Garcia Marco J; Houlihan A; Que TH; Catovsky D
    Leukemia; 1994 Oct; 8(10):1640-5. PubMed ID: 7523797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expanded antigen-experienced CD160
    Bozorgmehr N; Okoye I; Oyegbami O; Xu L; Fontaine A; Cox-Kennett N; Larratt LM; Hnatiuk M; Fagarasanu A; Brandwein J; Peters AC; Elahi S
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33931471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD160 signaling mediates PI3K-dependent survival and growth signals in chronic lymphocytic leukemia.
    Liu FT; Giustiniani J; Farren T; Jia L; Bensussan A; Gribben JG; Agrawal SG
    Blood; 2010 Apr; 115(15):3079-88. PubMed ID: 20164468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of CD5 in B-cell chronic lymphoproliferative diseases by flow cytometry: a strong expression in B-cell chronic lymphocytic leukemia.
    Cavalcanti Júnior GB; Sales VS; Cavalcanti e Silva DG; Lopes MC; Paiva Ade S; da Fonseca HE; do Nascimento Júniors FF; Fernandes MZ
    Acta Cir Bras; 2005; 20 Suppl 1():101-7. PubMed ID: 16186976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD11c (LEU-M5) expression characterizes a B-cell chronic lymphoproliferative disorder with features of both chronic lymphocytic leukemia and hairy cell leukemia.
    Hanson CA; Gribbin TE; Schnitzer B; Schlegelmilch JA; Mitchell BS; Stoolman LM
    Blood; 1990 Dec; 76(11):2360-7. PubMed ID: 1701669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mantle cell lymphoma with chronic lymphocytic leukemia-like features: a diagnostic mimic and pitfall.
    Qiu L; Xu J; Tang G; Wang SA; Lin P; Ok CY; Garces S; Yin CC; Khanlari M; Vega F; Medeiros LJ; Li S
    Hum Pathol; 2022 Jan; 119():59-68. PubMed ID: 34767860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Positive predictive value of CD200 positivity in the differential diagnosis of chronic lymphocytic leukemia.
    Sorigue M; Magnano L; Miljkovic MD; Nieto-Moragas J; Santos-Gomez M; Villamor N; Junca J; Morales-Indiano C
    Cytometry B Clin Cytom; 2020 Sep; 98(5):441-448. PubMed ID: 31692239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different levels of CD52 antigen expression evaluated by quantitative fluorescence cytometry are detected on B-lymphocytes, CD 34+ cells and tumor cells of patients with chronic B-cell lymphoproliferative diseases.
    Klabusay M; Sukova V; Coupek P; Brychtova Y; Mayer J
    Cytometry B Clin Cytom; 2007 Sep; 72(5):363-70. PubMed ID: 17428002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD200 expression may help in differential diagnosis between mantle cell lymphoma and B-cell chronic lymphocytic leukemia.
    Palumbo GA; Parrinello N; Fargione G; Cardillo K; Chiarenza A; Berretta S; Conticello C; Villari L; Di Raimondo F
    Leuk Res; 2009 Sep; 33(9):1212-6. PubMed ID: 19230971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD200 Expression in Diagnostic and Prognostic Assessment of Mature B Cell Lymphophoproliferative Neoplasms.
    El Din Fouad NB; Ibrahim NY; Abdel Aziz RS; Ibrahim SK
    Asian Pac J Cancer Prev; 2018 Dec; 19(12):3383-3392. PubMed ID: 30583344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of CD200 expression and CD20 antibody binding capacity in differentiating chronic lymphocytic leukemia from other chronic lymphoproliferative disorders.
    Poongodi R; Varma N; Naseem S; Parveen B; Varma S
    Indian J Pathol Microbiol; 2018; 61(1):50-57. PubMed ID: 29567884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative flow cytometry for the differential diagnosis of leukemic B-cell chronic lymphoproliferative disorders.
    D'Arena G; Musto P; Cascavilla N; Dell'Olio M; Di Renzo N; Carotenuto M
    Am J Hematol; 2000 Aug; 64(4):275-81. PubMed ID: 10911380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cut-off levels of CD23 expression in the differential diagnosis of MCL and CLL.
    Barna G; Reiniger L; Tátrai P; Kopper L; Matolcsy A
    Hematol Oncol; 2008 Sep; 26(3):167-70. PubMed ID: 18381689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD5- B-cell lymphoproliferative disorders presenting in blood and bone marrow. A clinicopathologic study of 40 patients.
    Shapiro JL; Miller ML; Pohlman B; Mascha E; Fishleder AJ
    Am J Clin Pathol; 1999 Apr; 111(4):477-87. PubMed ID: 10191767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.